Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Quantifying Drug Combination Synergy along Potency and Efficacy Axes.

Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR, Quaranta V.

Cell Syst. 2019 Feb 27;8(2):97-108.e16. doi: 10.1016/j.cels.2019.01.003. Epub 2019 Feb 20.

PMID:
30797775
2.

A Nonquiescent "Idling" Population State in Drug-Treated, BRAF-Mutated Melanoma.

Paudel BB, Harris LA, Hardeman KN, Abugable AA, Hayford CE, Tyson DR, Quaranta V.

Biophys J. 2018 Mar 27;114(6):1499-1511. doi: 10.1016/j.bpj.2018.01.016.

3.

Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.

Hardeman KN, Peng C, Paudel BB, Meyer CT, Luong T, Tyson DR, Young JD, Quaranta V, Fessel JP.

Sci Rep. 2017 Feb 16;7:42604. doi: 10.1038/srep42604.

4.

An unbiased metric of antiproliferative drug effect in vitro.

Harris LA, Frick PL, Garbett SP, Hardeman KN, Paudel BB, Lopez CF, Quaranta V, Tyson DR.

Nat Methods. 2016 Jun;13(6):497-500. doi: 10.1038/nmeth.3852. Epub 2016 May 2.

Supplemental Content

Loading ...
Support Center